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res ponse rate of 38%), and patients with depres sive symptoms could have been more inclined to consent than those without such symptoms. Furthermore, initial inclusion cri teria were weighted towards patients with depressive symptoms. This sample bias implies that the reported preva lence of depression in the study cannot be extrapo lated to community or outpatient samples, but this should not affect the overall valida tion results. Second, compared with scores reported in other studies of patients with PD, the ratingscale scores reported by Williams et al. 8 were generally lower, which resulted in recommended cutoff scores for a diagnosis of depres sion that were equal to, or even below, those recom mended in the general popula tion. The authors note that a higher cutoff score was expected, but cannot provide a pl ausible explanation for their outcome.
The finding that most depression rating scales perform equally well for screening in patients with PD is reassuring given that these scales are all frequently used in research and clinical practice. Depression scale properties were robust across demo graphic and clinical characteristics, suggest ing that these scales are applicable to many PD populations. However, the discrimina tive validity of these scales for other mood syndromes, such as anxiety disorders and apathy, was not assessed by Williams and colleagues. Furthermore, as in most valida tion studies, patients with cognitive decline were excluded. Individuals with PD and cognitive decline are at risk of depression, yet no reliable screening instruments exist for this subgroup of patients.
None of the scales studied is capable of capturing depressive symptoms or changes in mood that are related to on-off fluctua tions in patients with motor and nonmotor fluctuations. Thus, although the findings of this study are robust in PD overall, diagno sis of depression in different stages of PD presents additional challenges that are not met by existing scales. One should also note that many of these scales were not developed for screening of depression, and the UPDRS depression item was designed for clinician based assessment rather than patient self reporting, which may have contributed to the poor performance of this scale.
In summary, Williams et al. 8 show the utility of a number of rating scales for screen ing for depression in PD. How ever, these instruments do not replace the need for a clinical diagnosis. As most scales have simi lar clinimetric properties, aspects of con venience and cost will be considered when choosing a particular instrument. In many scenarios, short patient completed scales could perform equally well as long and/or clinicianrated scales that require training-a finding that could influence the design of largescale trials or epidemiologic al studies in PD.
Notably, the performance of the nine scales for rating depression severity in PD was not examined. The ability of scales to measure change in depressive status may differ considerably from their performance as a screening tool. In the Movement Dis order Society's published critique of depres sion rating tools, 4 the scales that gave the most accurate measurement of depression severity were different from those that were optimal for detecting depressive disorders. Whereas screening scales may be useful in clinical trials as tools to implement inclu sion or exclusion criteria, scales that measure severity will be more useful for assessing treatment responses. Construct validity, divergent validity for diagnosis of other syndromes, and clinimetric perfor mance in different PD subgroups have not been studied for most scales. These charac teristics require further investigation, and validation of scales with new assessment methods, such as the Item Response Theory, are still awaited.
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Insulin resistance and AD -extending the translational path
Suzanne Craft
Two recent studies have carefully characterized amyloid-related brain insulin resistance in animal models of, and patients with, Alzheimer disease (AD). The researchers show that exendin-4, a glucagon-like peptide 1 receptor agonist, ameliorates pathology and symptoms in a mouse model of AD, suggesting a novel therapeutic approach to this disease. 2 The study confirms previous reports that a key signa ture of insulin resistance-phosphorylation of insulin receptor substrate 1 at serine residues 312, 616, or 636 (IRS1pSer312, 616 or 636)-exists in the AD brain in basal states, 4 and extends these findings using ex vivo insulinreceptor stimu lation to provide evidence of functional insu lin resistance. Although these results are intriguing, caution is warranted when inter preting results from ex vivo stimulation of post mortem brain tissue. The researchers should be commended for their careful control of the time interval from death to postmortem, and for providing data from rodent studies to validate and support the findings in humans. 2 Such controls, how ever, cannot entirely correct for variable causes of death, or for differing disease states immediately before death, which can greatly affect tissue respon sivity to various interventions. Nevertheless, the authors demonstrate convincingly that postmor tem brain tissue from patients with AD is less responsive to nearphysiological doses of insulin than is tissue from nonAD cases.
One mechanism that has been proposed to underlie brain insulin resistance in AD is neurotoxicity mediated by oligomeric amyloidβ. In the study by Talbot et al., amyloid load in control, MCI and AD cases was negatively correlated with the level of tyrosine phosphorylation of the insulin receptor, and showed positive corre lation with levels of IRS1 serine kinases. 2 Importantly, high levels of insulin resist ance markers were associated with poor performance on tests of working and epi sodic memory, independently of levels of amyloid and neurofibrillary tangles, sug gesting that insulin signalling has a direct effect on cognitive status. This observation may help to explain the finding that adults with either amnestic MCI or nonamnestic MCI (the latter group being presumed not to have prodromal AD) showed increased basal levels of IRS1 serine kinases. How ever, the researchers did not conduct ex vivo stimulation studies to determine whether both groups have comparable functional insulin resistance.
The question remains, therefore, as to whether insulin resistance has a specific pathogenic role in AD, or whether it repre sents a brain stress response to oligomeric amyloidβ. Increased brain insulin resist ance in nonamnestic MCI could be due to another stressinducing stimulus such as brain ischaemia. Conversely, induction of peripheral insulin resistance is known to modulate levels of amyloidβ in animal and human models, [5] [6] [7] suggesting that insulin resistance might precede eleva tions in oligo meric amyloidβ in a subset of adults with AD. Further work is required to elucidate the relationship between insulin resistance in the brain and in the periphery. Although most of the patients studied did not have diabetes, it is worth noting that peripheral insulin resistance is a patho logical condition that commonly occurs in the absence of diabetes, as compensatory hyper insulinaemia enables glucose to be maintained at levels below the threshold for diagnosis of diabetes.
The companion paper by Bomfim et al. 3 takes the story of brain insulin resistance and AD further down the path to clinical translation. Whether results of their studies of human basal IRS1pSer overlap with the data presented by Talbot et al. 2 is unclear, as both studies included cases from the same University of Pennsylvania brain bank. Several additional experiments conducted in this second study, however, provide important new information. In one such experiment, Bomfim et al. used a primate model of AD in which adult cynomolgus monkeys received intra cerebroventricular infusions of amyloidβ oligomers. 3 They observed increased IRS1pSer636 levels in the hippocampus and temporal cortex of treated monkeys compared with a sham operated monkeys. Elevated levels of phosphorylated cJun Nterminal kinase -which has been linked to IRS1 serine phosphorylation in dia betes and periph eral insulin resistance-were also detected in these brain regions. The investigators reported comparable findings in APP/PS1 mice (an animal model of AD), corrobo rating previous findings in 3xTgAD mice. 3 These results support the poten tial for oligo meric amyloidβ to induce brain insulin resistance.
The next experiments by Bomfim et al. addressed possible therapeutic approaches to block the ADpromoting effects of insulin resistance. In neuronal cells in culture, both insulin and exendin4, an insulinotropic agonist of the glucagonlike peptide 1 (GLP1) receptor, prevented the increased serine phosphorylation and decreased tyro sine phosphorylation of IRS1 caused by application of amyloidβ. In vivo, intra peri toneal injection of exendin4 in APP/PS1 mice reduced hippo campal IRS1 serine phosphorylation and amyloid burden, while improving spatial memory. 3 The effects of exendin4 are encouraging, although they might not be directly attribut able to GLP1 receptormediated effects in the brain. Indeed, GLP1 receptor agonists have welldocumented effects on peripheral variables, including insu lin levels, dyslipi daemia, blood pressure, and other vascular factors, 8 which have all been shown to affect brain insulin signal ling pathways, amyloid burden, and memory in rodent models of AD. Future studies aimed at relating meta bolic parameters to observed brain changes will help to address this issue.
Although the two recent papers 2,3 pro pose that GLP1 receptor agonists have superior efficacy to interventions that raise insulin levels in the brain, no headtohead comparisons were made, and both insulin and exendin4 had bene ficial effects. Addi tionally, as would be predicted on the basis of these results, intranasal insulin has shown therapeutic benefit in adults with earlystage AD in a phase II clinical trial. Thus, both approaches could have merit, and the broader the range of therapeutic options to address defective brain insulin signalling in AD, the better.
In summary, the careful characterization of defects in brain insulin signalling and the reversal of AD pathology and symptoms by correction of these defects in in vivo models represent considerable advances in our 
